Female infertility: who works on it

One card per institution. Pick a target or a country to narrow the list.

• All targets
• GLP-1 2
• SIRT1 0
• EGFR 0
• PI3K 0
• AKT 0
• ESR1 0
• FAK 0
• JAK 0
• mTOR 0
• RANKL 1
• STAT3 0
• STING 0
• TNF 0

24 of 123 institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• NIH NIAID · R01

  Mycoplasma genitalium in Women: Natural History, Clinical Sequelae, and Host-Microbiome-Mediated Clearance

  University of Maryland Baltimore· Baltimore, United States· US$804,984 awarded in fiscal year 2026· until Aug 2031

• NIH NICHD · R61

  Toll-Like Receptor 4 Antagonism for Infertility Management in Polycystic Ovary Syndrome

  University of California-Irvine· Irvine, United States· US$435,691 awarded in fiscal year 2026· until Jun 2028

• NIH NIEHS · R01

  Investigating ovotoxic mechanisms of PFAS

  Iowa State University· Ames, United States· US$758,139 awarded in fiscal year 2026· until Jun 2031

• NIH NIGMS · R35

  Mechanisms regulating spindle assembly and chromosome segregation in oocyte acentrosomal meiosis

  Rutgers, the State Univ of N.j.· Piscataway, United States· US$431,750 awarded in fiscal year 2026· until Aug 2031

• NIH NICHD · R43

  FertiliChip: An Innovative Fallopian Tube-on-Chip Model for Women's Reproductive Health Research

  Cfd Research Corporation· Huntsville, United States· US$399,978 awarded in fiscal year 2026· until Sept 2027

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Cell type-specific endometrial dysfunctions across the menstrual cycle and their potential for drug interventions in polycystic ovary syndrome (POTRET)

  Karolinska Institutet· Stockholm, Sweden· EU contribution €236,340· until Jul 2028

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Long live the oocyte: studying protein lifespan in oocyte health (ProteOOcyte)

  Fundacio Centre de Regulacio Genomica· Barcelona, Spain· EU contribution €194,075· until Mar 2027

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC

  Hormone-microbiome interactions as a key-player in female health (HEROINE)

  Technische Universitaet Muenchen· Muenchen, Germany· EU contribution €1,499,485· until May 2027

  The disease is named only in the funder's project summary, not in the title.

8 of 76 running projects, newest first. Listed amounts together: US$35.9m + €1.9m.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Withdrawn

  150 IU vs. 225 IU FSH in Normal Responders: The OPTIMAL-DOSE Trial

  NCT07346235· American Hospital 2 Kosovo· Updated 29 Oct 2026

  “Ethics approval was not obtained. The study was withdrawn before any participants were enrolled.”Registry text, quoted unchanged. Source

• Withdrawn

  Uterine Transplant in Absolute Uterine Infertility (AUIF)

  NCT02741102· Brigham and Women's Hospital· Updated 15 Oct 2026

  “Attempts to renew our protocol have not been accepted. Also, composition of the team and institutional goals have changed.”Registry text, quoted unchanged. Source

• Terminated

  The REBALANCE Study - a Prospective, Multicenter, Randomized, Pivotal Study of the May Health System

  NCT06206746· May Health· Updated 8 Sept 2026

  “Business decision by sponsor to terminate the study”Registry text, quoted unchanged. Source

• Terminated

  Sex or no Sex: That is the Question.

  NCT04880590· Fundación Santiago Dexeus Font· Updated 8 Sept 2026

  “The study was discontinued due to difficulties in patient recruitment”Registry text, quoted unchanged. Source

• Suspended

  Optimal Timing of Euploid Day 6 Blastocyst Transfer in Frozen HRT Cycles, Day 6 or Day 7 of Progesterone Administration.

  NCT05980091· ART Fertility Clinics LLC· Updated 25 Jun 2026

  “Difficulty of enrolling and recruiting patients”Registry text, quoted unchanged. Source

• Suspended

  SCLife®-UT hUC-MSCs Advanced Therapy Medicinal Products (hUC-MSCs ATMPs) for Patients With Thin Endometrial Infertility

  NCT06503471· Sclnow Biotechnology Co., Ltd.· Updated 23 Apr 2026

  “Lack of financial support”Registry text, quoted unchanged. Source

• Terminated

  Impact of Operation on Fertility for Women With Severe Endometriosis

  NCT04610710· Horsens Hospital· Updated 10 Mar 2026

  “Enrolment of study participants was too challenging and long-drawn.”Registry text, quoted unchanged. Source

• Withdrawn

  Internet-based Intervention to Promote a Healthy Lifestyle on the Reproductive Parameters of Overweight and Obese Women

  NCT04275869· Cardenal Herrera University· Updated 12 Feb 2025

  “No participants enrolled”Registry text, quoted unchanged. Source

• Terminated

  PRogrammed Versus Modified Natural Cycle After Euploid Failed Embryo Transfer

  NCT06074055· Reproductive Medicine Associates of New Jersey· Updated 7 Feb 2025

  “recruitment issues”Registry text, quoted unchanged. Source

• Terminated

  Ibuprofen Versus Ketorolac for Pain Relief During Hysterosalpingogram

  NCT05190341· Madigan Army Medical Center· Updated 24 Dec 2024

  “IRB voted to terminate the protocol for noncompliance”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• Youth Outlook on Life Opportunities Study

  NCT05026619· National University of Singapore· Source

• A Study to Investigate Mibavademab in Adult Women With Functional Hypothalamic Amenorrhea

  NCT07235917· Regeneron Pharmaceuticals· Source

• hCG Priming in Women With Diminished Ovarian Reserve

  NCT07108621· Kristine Loessl· Source

• The REBALANCE Study - a Prospective, Multicenter, Randomized, Pivotal Study of the May Health System

  NCT06206746· May Health· Source

• Purpose to Evaluate the Effectiveness of the Superovulation Stimulation Protocol Using Human Chorionic Gonadotropin (hCG) by Demonstrating Its Equivalence to Standard Controlled Ovarian Stimulation Protocols in Terms of Oocytes Retrieved, Blastulation While Maintaining an Economic Advantage

  NCT07771283· LTD "EKODNIPRO", Medical centre Medical Plaza Dnipro· Source

• Autologous Ovarian Tissue Transplantation

  NCT03496636· University of Pittsburgh· Source

• Aromatherapy for Mental Health Promotion in IVF Patients

  NCT07480668· Federal University of Minas Gerais· Source

• Impact of Day 2 Versus Day 3 Fresh Embryo Transfer on Live Birth Rate in Poor-Prognosis Patients

  NCT07533695· Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University· Source

• Association Between Serum Thyroid-stimulating Hormone (TSH) and Intracytoplasmic Sperm Injection (ICSI) Outcome in Women Undergoing ICSI

  NCT07449260· Cairo University· Source

• Effect Of The Mediterranean Diet On Zonulin And Infertility

  NCT07072936· SINEM BAYRAM· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 8
• Mendelian Randomization Analysis 12
• CRISPR-Cas Systems 2
• Gene Expression Profiling 10
• Exome Sequencing 20
• Proteomics 10
• Metabolomics 11
• Flow Cytometry 1
• Immunohistochemistry 5
• Magnetic Resonance Imaging 6
• Machine Learning 8
• Deep Learning 2
• Cohort Studies 31
• Genome-Wide Association Study 14

See which targets of this disease your abstract mentions, and go to the people working on them.